B-CELL NON-HODGKIN LYMPHOMA

This study tests whether the drug anakinra can prevent or reduce severe side effects like brain problems and cytokine release syndrome caused by CAR-T cell therapy. About 62 adults with certain B-cell blood cancers who are getting CAR-T treatment will receive anakinra. The goal i…

This study tests a new, fast-made CAR-T cell therapy (UF-KURE19) for people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The main goal is to check safety and find the right dose in 21 adults. Researchers also look at how well the therapy shri…

This early-phase study tests a new treatment for people with certain B-cell blood cancers (lymphoma, ALL, or CLL) that have returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack cancer ce…

This study tests a drug called blinatumomab given after a stem cell transplant to help prevent relapse in people with B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma. About 44 participants will receive the drug as maintenance therapy. The goal is to see if it i…

This study aimed to see if the drug N-803 is safe and tolerable for people with B-cell non-Hodgkin lymphoma who had already received CAR T-cell therapy. It planned to enroll adults whose cancer had responded to CAR T treatment. However, the study was withdrawn before any particip…

This early-stage trial is testing a new drug called AZD0486 in people with B-cell non-Hodgkin lymphoma, a type of blood cancer. The drug is a bispecific antibody designed to help the body's immune cells find and kill cancer cells. About 226 participants who have already tried at …

This study tests a new drug called ARQ 531 (nemtabrutinib) in about 190 people with blood cancers like lymphoma or leukemia that have returned or not responded to other treatments. The goal is to check the drug's safety and how well it works. Participants take the drug as a table…

This early-phase study tests a new drug called JNJ-80948543 in people with non-Hodgkin lymphoma or chronic lymphocytic leukemia whose cancer has returned or not responded to other treatments. The drug works by redirecting the body's T-cells to attack cancer cells. The main goals …

This study tests a new treatment for people with relapsed or hard-to-treat B-cell Non-Hodgkin lymphoma. It combines two immune-based therapies: a bispecific antibody and CAR-T cells. The goal is to see if the combination is safe and helps control the cancer. About 48 adults will …

This study tests whether adding the drug acalabrutinib to CAR T-cell therapy (a treatment that uses a patient's own immune cells to fight cancer) is safe and effective for adults with certain types of B-cell lymphoma. About 23 participants will receive the combination. The goal i…

This study tests whether combining two drugs, pembrolizumab and tazemetostat, can help prevent aggressive B-cell non-Hodgkin lymphoma from returning after stem cell transplant or CAR T-cell therapy. About 32 adults who have already had or are about to have one of these treatments…

This study looks at whether tracking tiny bits of tumor DNA in the blood (ctDNA) can help predict how B-cell non-Hodgkin lymphoma will progress. Researchers will collect blood samples from 60 patients before and during treatment. The goal is to see if changes in ctDNA levels matc…

This study looks at whether a blood test can spot signs of lymphoma coming back after chemotherapy, possibly earlier than regular CT scans. About 500 adults with aggressive B-cell Non-Hodgkin lymphoma will give blood samples after treatment. The goal is to see if this test could …